echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bispecific fusion protein treatment of metastatic uveal melanoma significantly improves overall response rate

    Bispecific fusion protein treatment of metastatic uveal melanoma significantly improves overall response rate

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    The American Association for Cancer Research (AACR) 2021 Annual Meeting will be held on April 10-15, 2021.


    Uveal melanoma is generally rare, but it is the most common eye cancer in adults, accounting for about 3-5% of all melanomas.


    Tebentafusp is a new type of bispecific fusion protein, which is formed by fusion of soluble TCR and anti-CD3 immune effector domain.


    In the phase 3 clinical study announced at the meeting, 378 patients with previously untreated metastatic uveal melanoma were randomly assigned at a ratio of 2:1 to receive tebentafusp or a regimen selected by the investigator for first-line treatment.


    The results showed that after a median follow-up of 14.


    In this study, adverse events related to tebentafusp treatment were predictable and controllable.


    As there is currently no standard treatment for patients with uveal metastatic melanoma.


    Article reference source:

    Bispecific Fusion Protein Tebentafusp Significantly Improves Overall Survival in Patients With Metastatic Uveal Melanoma

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.